

University of Mississippi

eGrove

Faculty and Student Publications

Pharmacy, School of

6-1-2021

Evidence that *Maackia amurensis* seed lectin (MASL) exerts pleiotropic actions on oral squamous cells with potential to inhibit SARS-CoV-2 infection and COVID-19 disease progression

Stephanie A. Sheehan
Rowan University

Kelly L. Hamilton
Rowan University

Edward P. Retzbach
Rowan University

Premalatha Balachandran
University of Mississippi, Research Institute Pharmaceutical Science

Follow this and additional works at: https://egrove.olemiss.edu/pharmacy_facpubs



Part of the [Pharmacy and Pharmaceutical Sciences Commons](#)

Recommended Citation

Sheehan, S. A., Hamilton, K. L., Retzbach, E. P., Balachandran, P., Krishnan, H., Leone, P., Lopez-Gonzalez, M., Suryavanshi, S., Kumar, P., Russo, R., & Goldberg, G. S. (2021). Evidence that *Maackia amurensis* seed lectin (Masl) exerts pleiotropic actions on oral squamous cells with potential to inhibit SARS-CoV-2 infection and COVID-19 disease progression. *Experimental Cell Research*, 403(1), 112594. <https://doi.org/10.1016/j.yexcr.2021.112594>

This Article is brought to you for free and open access by the Pharmacy, School of at eGrove. It has been accepted for inclusion in Faculty and Student Publications by an authorized administrator of eGrove. For more information, please contact egrove@olemiss.edu.



Evidence that *Maackia amurensis* seed lectin (MASL) exerts pleiotropic actions on oral squamous cells with potential to inhibit SARS-CoV-2 infection and COVID-19 disease progression

Stephanie A. Sheehan^a, Kelly L. Hamilton^a, Edward P. Retzbach^a, Premalatha Balachandran^b, Harini Krishnan^c, Paola Leone^d, Moises Lopez-Gonzalez^e, Shradha Suryavanshi^e, Pradeep Kumar^e, Riccardo Russo^e, Gary S. Goldberg^{a,*}

^a Department of Molecular Biology, And Graduate School of Biomedical Sciences, School of Osteopathic Medicine, Rowan University, Stratford, NJ, 08084, USA

^b National Center for Natural Products Research, Research Institute of Pharmaceutical Sciences, School of Pharmacy, University of Mississippi, MS, 38677, USA

^c Department of Physiology and Biophysics, School of Medicine, Stony Brook University Stony Brook, NY, 11794-8661, USA

^d Department of Cell Biology and Neuroscience, Cell and Gene Therapy Center, And Graduate School of Biomedical Sciences, School of Osteopathic Medicine, Rowan University, Stratford, NJ, 08084, USA

^e Regional Bio-containment Laboratory, Center for COVID-19 Response and Pandemic Preparedness (CRP2), Rutgers-New Jersey Medical School, Newark, NJ, 07103, USA

ARTICLE INFO

Keywords:

COVID-19
SARS-CoV-2
Oral squamous cells
Maackia amurensis
Lectin
ACE2
Infection
Inflammation

ABSTRACT

COVID-19 was declared an international public health emergency in January, and a pandemic in March of 2020. There are over 125 million confirmed COVID-19 cases that have caused over 2.7 million deaths worldwide as of March 2021. COVID-19 is caused by the SARS-CoV-2 virus. SARS-CoV-2 presents a surface “spike” protein that binds to the ACE2 receptor to infect host cells. In addition to the respiratory tract, SARS-CoV-2 can also infect cells of the oral mucosa, which also express the ACE2 receptor. The spike and ACE2 proteins are highly glycosylated with sialic acid modifications that direct viral-host interactions and infection. *Maackia amurensis* seed lectin (MASL) has a strong affinity for sialic acid modified proteins and can be used as an antiviral agent. Here, we report that MASL targets the ACE2 receptor, decreases ACE2 expression and glycosylation, suppresses binding of the SARS-CoV-2 spike protein, and decreases expression of inflammatory mediators by oral epithelial cells that cause ARDS in COVID-19 patients. In addition, we report that MASL also inhibits SARS-CoV-2 infection of kidney epithelial cells in culture. This work identifies MASL as an agent with potential to inhibit SARS-CoV-2 infection and COVID-19 related inflammatory syndromes.

1. Background

SARS-CoV-2 has infected over 125 million people and caused over 2.7 million deaths around the world in just 16 months (as of March 2021) [1]. The SARS-CoV spike protein targets the angiotensin converting enzyme 2 (ACE2) receptor on host cells. This interaction is mediated by a receptor binding domain (RBD) in the S1 portion of the spike protein that recognizes the human ACE2 extracellular domain [2, 3]. Transmembrane protease serine 2 (TMPRSS2) and furin cleave a polybasic sequence to unlink the S1 and S2 domains in the SARS spike protein to promote virial cell entry [3,4].

Lung epithelium, primarily T2 but also T1 cells, are considered prime

SARS-CoV-2 infection sites [5,6]. However other cells can be infected, including salivary gland and nasal epithelial cells [6–8]. ACE2 and furin protease are also highly expressed by human oral squamous epithelial cells of the mucosa and tongue where they can act as viral infection sites [9–11]. SARS-CoV-2 activates inflammatory pathways involving STAT3, IL6, and TNF that cause inflammation leading to pathologies including acute respiratory distress syndrome (ARDS) [12].

The SARS-CoV-2 spike and host ACE2 proteins are both heavily glycosylated with sialic acids needed for viral infection. The SARS-CoV-2 spike protein has at least 22 N-linked glycosylation sequons per protomer, and about 15% of these glycans contain at least one sialic acid residue [3,13,14]. The human ACE2 receptor contains 7 N-linked and 3

* Corresponding author. B307 Science Center, Molecular Biology, Rowan-SOM, Stratford, NJ, 08084, USA.

E-mail address: gary.goldberg@rowan.edu (G.S. Goldberg).

<https://doi.org/10.1016/j.yexcr.2021.112594>

Received 28 January 2021; Received in revised form 28 March 2021; Accepted 31 March 2021

Available online 3 April 2021

0014-4827/© 2021 Elsevier Inc. All rights reserved.

O-linked glycans, and they all contain sialic acid residues [15].

Lectins recognize specific glycosylation motifs, and can be used as antiviral agents [16]. In particular *Maackia amurensis* seed lectin (MASL) has a strong affinity for sialic acid modified proteins, and targets specific receptors to inhibit viral infection [16,17], cancer progression [18,19], and inflammation [20,21]. Indeed, the effect of MASL on oral squamous cell carcinoma is being investigated in Phase I human clinical trial [22]. However, effects of MASL on SARS-CoV-2 infection and inflammatory pathways have not been described. Here, we report that MASL targets the ACE2 receptor, inhibits SARS-CoV-2 spike binding, and decreases the expression of ACE2, furin, sialic acid glycosylases, and inflammatory cytokines in human OSCC cells. In addition, we report that MASL also inhibits SARS-CoV-2 infection of mammalian kidney epithelial cells. These data suggest that MASL offers an opportunity to target oral epithelial cells by oral administration to help combat SARS-CoV-2 infection and disease progression.

2. Methods

2.1. Cell culture and imaging

HSC-2 cells were maintained in DMEM (Hyclone SH30021) supplemented with 25 mM HEPES (Hyclone SH30237) and FBS (Seradigm 1400–500) at 37 °C in 5% CO₂ and 100% humidity as described [18]. For biochemical analysis, cells at 80% confluence on 6 well tissue culture cluster plates (Falcon 353224) were exposed to MASL (Sentrimed) at concentrations and time periods indicated in text. Cells were then rinsed with PBS, transferred to microcentrifuge tubes with rubber policemen, pelleted at 14,000×g, aspirated, and frozen at –80 °C. Cells cultured on 35 mm poly-D-lysine-coated glass bottom culture dishes (MatTek P35GC-1.5-14-C) were used for live cell imaging. Cells were incubated for 1 h in PBS with 0.4 mg/ml ACE2 antibody (Proteintech 66699-I-Ig) conjugated to Alexa Fluor 647 (Molecular Probes A30009) and 1.4 μM MASL (Sentrimed) conjugated to Alexa Fluor 595 (Molecular Probes A11005) to examine MASL and ACE2 localization. Cells were incubated for 1 h in PBS with 2 μM SARS-CoV-2 spike protein (Ray-Biotech 230–30161) labeled with Alexa Fluor 555 (Molecular Probes A30007) with and without 1.4 μM MASL to examine the effect of MASL on spike binding. This glycosylated SARS-CoV-2 S1 spike protein (genbank QHD43416 Val16 - Gln690) is produced by HEK293 cells and migrates at ~120 kD and ~75 kD before and after glycosylase treatment. After incubation, cells were rinsed with PBS and examined by confocal microscopy on a Carl Zeiss Axio Observer Z1 equipped with a Plan-Apochromat 63× objective, apotome 2, filter sets to detect Alexa Fluor 555 and DIC with a Zeiss AxioCam Mrc camera Rev3 equipped with an INU series Tokai Hit Stage Top Incubator and Zen Pro 2.3 software as previously described [18,23]. Signal intensity was quantitated with ImageJ software.

2.2. RNA isolation and sequence analysis

Transcriptome analysis was performed as described [24] and specified as follows. Total RNA was extracted from frozen cell pellets using Qiagen RNeasy Plus Universal mini kit according to manufacturer's instructions (Qiagen, Hilden, Germany). RNA library preparations and sequencing reactions were conducted at GENEWIZ, LLC. (South Plainfield, NJ, USA). RNA samples were quantified using Qubit 2.0 Fluorometer (Life Technologies, Carlsbad, CA, USA) and RNA integrity was checked using Agilent TapeStation 4200 (Agilent Technologies, Palo Alto, CA, USA). RNA sequencing libraries were prepared using the NEBNext Ultra RNA Library Prep Kit for Illumina following manufacturer's instructions (NEB, Ipswich, MA, USA). Briefly, mRNAs were first enriched with Oligo(dT) beads. Enriched mRNAs were fragmented for 15 min at 94 °C. First strand and second strand cDNAs were subsequently synthesized. cDNA fragments were end repaired and adenylated at 3' ends, and universal adapters were ligated to cDNA fragments,

followed by index addition and library enrichment by limited-cycle PCR. The sequencing libraries were validated on the Agilent TapeStation (Agilent Technologies, Palo Alto, CA, USA), and quantified by using Qubit 2.0 Fluorometer (Invitrogen, Carlsbad, CA) as well as by quantitative PCR (KAPA Biosystems, Wilmington, MA, USA). Sequencing libraries were clustered on 1 lane of a flowcell. After clustering, the flowcell was loaded on the Illumina HiSeq instrument (4000 or equivalent) according to manufacturer's instructions. The samples were sequenced using a 2x150bp Paired End (PE) configuration. Image analysis and base calling were conducted by the HiSeq Control Software (HCS). Raw sequence data generated from Illumina HiSeq was converted into fastq files and de-multiplexed using Illumina's bcl2fastq 2.17 software. One mismatch was allowed for index sequence identification. Raw data were converted to transcripts per million (TPM) values used to calculate percent expression compared to untreated control cells. Data from this study can be accessed with BioSample accession SAMN14979424 (<https://www.ncbi.nlm.nih.gov/biosample/14979424>).

2.3. Western blotting

Western blotting was performed as described previously [18,25]. Cells were lysed in lysis buffer (2% SDS, 10% glycerol, 10 mM EDTA, 50 mM DTT, 50 mM NaF, 0.2 mM Na₂VO₄, and 1 mM PMSF in 62.5 mM Tris pH 6.8), sonicated, and clarified by centrifugation. Protein (15 μg/lane) was resolved by SDS-PAGE, transferred to Immobilon-P membranes (Millipore IH1079562), and incubated with antisera specific for ACE2 (Proteintech 66699-I-Ig) and β-actin (Sigma A1978). Primary antibodies were recognized by secondary antibody conjugated to horseradish peroxidase (Invitrogen 31430) and detected using enhanced chemiluminescence (Thermo Scientific 32106). Signal intensity was quantitated with ImageJ software. Membranes were stained with India ink to verify equal loading and transfer after blotting.

2.4. Transcriptional reporter assays

Luciferase reporter constructs were transfected into HeLa cells as previously described [26]. Pathways, targets, and inducers included Stat3 (TGCTTCCCGAATTCCCGAATTCCCGAATTCCCGAATTCCCGAAT TCCCGAACGT) induced by IL6 (50 ng/ml, R&D Systems 206-IL-010) [26] and.

NFκB (GCTACAAGGGACTTTCGCTGGGGACTTTCAGG) induced by PMA [26,27]. Twenty four hours after transfection, cells were incubated with pathway inducers for 30 min, treated with MASL for 4–6 h, lysed with One-Glo luciferase assay reagents (Promega), and luminescence was measured with a GloMax Multi + detection system equipped with Instinct Software (Promega). Values were normalized to untreated HeLa control cells.

2.5. Viral infection assay

The activity of MASL on SARS-COV-2 (2019-nCoV/USA-WA1/2020) was determined as described previously [28]. Briefly, Vero E6 cells (ATCC CRL-1586) were plated in 96-well white tissue culture plates (20,000 cells/well) and incubated for 24 h at 37 °C in 5% CO₂ in DMEM supplemented with 2% FBS. Cells were then incubated for 90 min with 0, 770, and 2310 nM MASL. Virus was then added at an MOI of 0.1 and incubated for 72 h before relative cell viability was determined using CellTiter-Glo® (Promega) according to manufacturer's instructions and luminescence was measured using a Cytation 3 plate reader (Biotek).

3. Results

SARS-CoV-2 spike proteins binds to ACE2 receptors on oral mouth and tongue epithelium to enable viral endocytosis, COVID-19 infection, and subsequent inflammation [29]. HSC-2 OSCC cells were used as a




Fig. 1. MASL colocalizes with ACE2 and inhibits SARS-CoV-2 spike protein binding to OSCC cells. (a) HSC-2 cells were incubated with 0.4 mg/ml Alexa 647 labeled ACE2 monoclonal antibody and 1.4 μ M Alexa 595 labeled MASL and examined by live cell confocal microscopy. Fluorescent, DIC, and merged images are shown as indicated (bar = 100 μ m). (b) Orthogonal imaging of MASL and ACE2 colocalization in cut out view indicated by arrows (bar = 20 μ m). (c) Intensity plot profile over distance in one focal plane of an observed area as indicated. (d) Cells were incubated with 2 μ M Alexa 555 labeled spike protein for 1 h with and without 1.4 μ M MASL. Fluorescent, DIC, and merged images are shown as indicated (bar = 200 μ m). (e) Fluorescence from a 15000 μ m² area of cells incubated with spike protein with and without MASL was quantitated with quadruple asterisks indicating $p < 0.0001$ by t -test and indicated (mean + SEM, $n = 4$).




Fig. 2. MASL affects expression of genes involved in SARS-CoV-2 infection and inflammation. HSC-2 cells were treated for 12 h with 0, 770, or 1925 nM MASL and examined by RNA-Seq. Expression of gene transcripts were quantitated and shown as percent of untreated control cells (mean + SEM, n = 2) with p values by ANOVA as indicated. (a) MASL inhibits ACE2, ADAM17, and furin mRNA levels. (b) MASL inhibits mRNA levels of glycosylases (C1galt, St6galnac1, and St6galnac2) needed for sialic acid modification of the ACE2 receptor. (c) MASL increases expression of anti-inflammatory transcripts (Hmxo1 and Il36rn), and decreases expression of pro-inflammatory (Nfkb1, Foxo1, Tnfsf10, Tlr4, and Tlr3) mRNA transcripts.




Fig. 3. MASL inhibits ACE2 receptor expression and glycosylation. (a) HSC-2 cells were treated for 12 h with 0, 770, or 1925 nM MASL and examined by Western blotting with apparent molecular weights shown as indicated. Primary and glycosylated ACE2 protein are evident at 92 and 120 kD, respectively (b) Protein expression was quantitated by image densitometry and shown as percent of untreated control cells (mean + SEM, n = 3) with p values by ANOVA as indicated.

model system for this study. These cells were derived from the mouth floor of a 69 year old male and are HPV negative [18,30,31]. *Maackia amurensis* seed lectin (MASL) targets sialic acid modified receptors on these cells within 2 min of exposure [18,32].

Previous studies report that *Maackia amurensis* lectin binds to α 2,3 and α 2,6 O-linked sialic acid residues on host cell receptor glycoproteins to inhibit sapovirus infection [17]. The SARS-CoV-2 spike protein and human ACE2 receptor are both decorated with sialic acid residues needed for viral infection [3,13–15]. Therefore, we proposed that MASL can associate with the human ACE2 receptor and/or the SARS-CoV-2 spike protein to prevent infection. Results from live cell imaging experiments indicate that MASL colocalizes with the ACE2 receptor on HCS-2 cells as shown in Fig. 1a–c. Accordingly, MASL effectively inhibited the ability of viral spike protein to target HSC-2 cells as shown in Fig. 1d and e.

In addition to interfering with interactions between spike and ACE2 proteins, MASL appears to inhibit ACE2 expression and glycosylation. MASL decreases ACE2 mRNA levels in HSC-2 cells by nearly 50% and 60% at 770 nM and 1925 nM, respectively, as shown in Fig. 2a. The human ACE2 receptor contains at least 10 moieties containing sialic acid (Neu5Ac or NANA) residues [15]. These modifications are catalyzed by the enzymes GalNAc-T, ST6GalNAc-1, and ST6GalNAc-2 [33,34]. As shown in Fig. 2b, MASL inhibits the expression of mRNA encoding these enzymes in a dose responsive manner. Taken together, these results suggest that MASL inhibits ACE2 expression and posttranslational sialic acid modification. These results are confirmed at the protein level by Western blotting. Treatment of cells with 1925 nM MASL for 12 h inhibited ACE2 protein expression and glycosylation by over 50% as shown in Fig. 3. In contrast, β -actin expression, which was used as a control, was either not affected or slightly increased (see Fig. 3).




Fig. 4. MASL affects NF κ B and STAT3 transcriptional activation pathways and SARS-CoV-2 infection. (a) HeLa cells transfected with Luciferase reporter constructs to detect NF κ B and STAT3 activity were incubated with 0, 3.08, 5.16, or 7.70 μ M MASL for 4–6 h as indicated. Luminescence values were normalized to untreated non-transfected control cells and are shown as percent control (mean + SEM, n = 2) with p values by ANOVA as indicated. (b) Vero E6 cells were incubated SARS-CoV-2 virus for 72 h in 0, 770, and 2310 nM MASL. Cell viability was measured and shown as percent control (mean + SEM, n = 4) with quadruple asterisk indicating p < 0.0001 by ANOVA as indicated. (c) Diagram illustrating how MASL reduces ACE2, ADAM17, and furin expression, and decreases inflammatory signaling events that would otherwise lead to activation of the IL6 amplifier implicated in COVID-19 induced ARDS.

After viral recognition, furin protease cleaves the SARS-CoV-2 spike protein at the cell membrane to promote membrane fusion and viral endocytosis [3,4]. After furin cleavage, a disintegrin and metalloproteinase 17 (ADAM17) generates mature inflammatory ligands including IL6 in response to SARS-CoV-2 infection [35,36]. Interestingly, MASL decreased furin and ADAM17 mRNA levels in HSC-2 cells by nearly 20% and 40% at 770 nM and 1925 nM, respectively, as shown in Fig. 2a.

Once activated in response to infection, IL6 activates STAT3 in epithelial cells [35,37]. STAT3 signaling induces the expression of cytokines including more IL6 and NF κ B [35,38]. IL6, STAT3, and NF κ B cooperate to induce the IL6 amplifier (IL6-Amp) which hyper-activates NF κ B to produce cytokines that cause multiple inflammatory responses [35,37]. This occurs in a variety of cells including chondrocytes [39], intestinal [40], lung [41,42], and dermal epithelium [43]. NF κ B can also induce IL6 production to induce vascular inflammation [44].

We utilized reporter transcriptional reporter assays to find that MASL inhibited STAT3 and NF κ B signaling activity in a dose responsive manner as shown in Fig. 4a.

NF- κ B regulates cytokine expression and inflammatory immune response to infection [45]. Accordingly, NF- κ B signaling has been implicated in the control of ACE2 expression and COVID-19 inflammatory pathologies [35,46,47]. If left unchecked, these infections induce FOXO1 expression in epithelial cells including oral mucosa, which induces the expression of toll-like receptors (TLRs) [48]. TLR signaling induces interleukin-36 (IL36) production, which induces IL6 expression [49]. IL6 then goes on to produce inflammatory cytokines in response to infections including tuberculosis in lung epithelial cells [41,42]. Heme oxygenase 1 (HMOX1) induces IL36RN expression, which acts as an IL36 antagonist to inhibit inflammation [50,51]. As shown in Fig. 2c, MASL increased both HMOX1 and IL36RN mRNA expression in a dose responsive manner. These data suggest that MASL utilizes HMOX1 to

induce IL36RN expression. Along with increasing the expression of anti-inflammatory mediators, MASL also decreased the expression of mRNA encoding inflammatory transcription factors NF κ B and FOXO1, as well as the inflammatory cytokine TNFSF10, and toll-like receptors TLR3 and TLR4 in a dose responsive manner as shown in Fig. 2c.

An established assay was used to investigate the effect of MASL on SARS-CoV-2 infection [28]. As shown in Figs. 4b and 770 nM and 1925 nM MASL significantly decreased viral toxicity in a dose responsive manner. These data indicate that MASL can inhibit the ability of the SARS-CoV-2 virus to infect mammalian cells.

4. Discussion

SARS-CoV-2 kills about 2% of infected individuals. This mortality rate is over 10 times higher than that of the seasonal influenza virus [52]. Remdesivir is currently approved to treat COVID-19 [53] and other drugs and vaccines are currently being deployed [54]. However, over 33,000 COVID-19 related deaths were reported in the United States during February of 2021 [55]. There is a clear need for new COVID-19 treatment options.

Severe acute respiratory distress syndrome (ARDS) is a major COVID-19 morbidity [56]. COVID-19 instigates chronic inflammation resulting in a “cytokine storm” that causes most ARDS mediated deaths [57–59]. COVID-19 also causes multisystem inflammatory syndrome (MIS) in children and adolescents. This hyper-inflammation leads to multiple organ failure and shock [60]. Treatments for these inflammatory syndromes include parenteral immunoglobulin and steroids with limited efficacy [61]. The IL-6 antibody blocker tocilizumab was found an effective treatment for CAR-T cell induced cytokine storm, and has been adopted as a treatment for COVID-19 inflammation [62–64].

Unlike antibodies, lectins can be taken orally to treat diseases [65–67] including cancer [65] and viral infections [16]. MASL targets sialic acid modified receptors to inhibit cancer progression and inflammation [18,19,21]. Results from this study indicate that MASL inhibits ACE2 expression, SARS-CoV-2 spike binding, and major components of the IL6 amplifier including STAT3, IL6, and NF κ B as illustrated in Fig. 4d. In addition to viral lung inflammation, IL6 signaling also triggers contact dermatitis and psoriasis in keratinocytes [43], as well as arthritic inflammation in chondrocytes [39]. COVID-19 inflammation shares inflammatory mechanisms with arthritis [12]. Indeed, COVID-19 infection causes arthralgia and myalgia in 15% and 44% of patients, respectively [68,69]. It should therefore be noted that MASL has been found to attenuate inflammatory NF κ B signaling and inflammation in chondrocyte cell culture, and can be administered orally to alleviate arthritis progression in mice [21]. In addition, MASL has also been reported to suppress interleukin induced psoriatic inflammation in reconstituted epidermis [70]. Taken together, data suggest that MASL has the potential to be used alone or in combination with other antiviral and anti-inflammatory agents for COVID-19 treatment.

Credit roles

Stephanie A. Sheehan, Conceptualization, Methodology, Data curation, Visualization. Kelly L. Hamilton, Conceptualization, Methodology, Data curation, Visualization. Edward P. Retzbach, Methodology, Data curation. Premalatha Balachandran, Conceptualization, Methodology, Data curation, Visualization. Harini Krishnan, Methodology, Data curation. Paola Leone, Conceptualization, Methodology. Moises Lopez-Gonzalez, Conceptualization, Methodology, Data curation, Visualization. Shraddha Suryavanshi, Conceptualization, Methodology, Data curation, Visualization. Pradeep Kumar, Conceptualization, Methodology, Data curation, Visualization. Riccardo Russo: Conceptualization, Methodology, Data curation, Visualization. Gary S. Goldberg, Conceptualization, Methodology, Data curation, Visualization, Supervision, Writing-Reviewing and Editing.

Declaration of competing interest

GSG has intellectual property and ownership in Sentrimed, Inc. which is developing agents that target PDPN to treat diseases including cancer and arthritis. PL is scientific cofounder of Bamboo Therapeutics and scientific advisory Board member of Agilis Biotherapeutics. Other authors have no conflicts to declare.

Acknowledgments

We are grateful for Todd Miller (Stony Brook Univ.) for technical support. This study was supported in part by funding from the Osteopathic Heritage Foundation, New Jersey Health Foundation, Sentrimed, Camden Health Research Initiative, and NIH grant CA235347 to GSG, a contract from the University of Mississippi Medical Center Cancer Institute to PB, and Bamboo Therapeutics (15–0190) and the NIH (NS088763-01A1) with additional support by the Canavan Research Illinois, the Ralph & Lois Silver Foundation, and Jacob’s Cure to PL.

References

- [1] World Health Organization, Coronavirus Disease (COVID-19) Weekly Epidemiological Update, 2021. March 26, 2021.
- [2] B.E. Martina, B.L. Haagmans, T. Kuiken, R.A. Fouchier, G.F. Rimmelzwaan, G. Van Amerongen, J.S. Peiris, W. Lim, A.D. Osterhaus, Virology: SARS virus infection of cats and ferrets, *Nature* 425 (2003) 915.
- [3] A.C. Walls, Y.J. Park, M.A. Tortorici, A. Wall, A.T. McGuire, D. Velesler, Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein, *Cell* 181 (2020) 281–292, e286.
- [4] M. Hoffmann, H. Kleine-Weber, S. Pohlmann, A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells, *Mol. Cell* 78 (2020) 779–784, e775.
- [5] F. Qi, S. Qian, S. Zhang, Z. Zhang, Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses, *Biochem. Biophys. Res. Commun.* 526 (2020) 135–140.
- [6] W. Sungnak, N. Huang, C. Becavin, M. Berg, R. Queen, M. Litvinukova, C. Talavera-Lopez, H. Maatz, D. Reichart, F. Sampaziotis, K.B. Worlock, M. Yoshida, J. L. Barnes, H.C.A.L.B. Network, SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes, *Nat. Med.* 26 (2020) 681–687.
- [7] L. Liu, Q. Wei, X. Alvarez, H. Wang, Y. Du, H. Zhu, H. Jiang, J. Zhou, P. Lam, L. Zhang, A. Lackner, C. Qin, Z. Chen, Epithelial cells lining salivary gland ducts are early target cells of severe acute respiratory syndrome coronavirus infection in the upper respiratory tracts of rhesus macaques, *J. Virol.* 85 (2011) 4025–4030.
- [8] S. Bertram, A. Heurich, H. Lavender, S. Gierer, S. Danisch, P. Perin, J.M. Lucas, P. S. Nelson, S. Pohlmann, E.J. Soilleux, Influenza and SARS-coronavirus activating proteases TMPRSS2 and HAT are expressed at multiple sites in human respiratory and gastrointestinal tracts, *PLoS One* 7 (2012), e35876.
- [9] M. Srinivasan, S.L. Zunt, L.I. Goldblatt, Oral epithelial expression of angiotensin converting enzyme-2: implications for COVID-19 diagnosis and prognosis, *BioRxiv* (2020). <https://doi.org/10.1101/2020.06.22.165035>.
- [10] B.-P. Lin, M. Zhong, H.-B. Gao, K.-B. Wu, M.-X. Liu, C. Liu, X.-H. Wang, J.-M. Chen, L.-H. Lee, C.-L. Qi, L.-H. Ge, L.-J. Wang, Significant expression of FURIN and ACE2 on oral epithelial cells may facilitate the efficiency of 2019-nCoV entry, *bioRxiv* (2020). <https://doi.org/10.1101/2020.04.18.047951>.
- [11] H. Xu, L. Zhong, J. Deng, J. Peng, H. Dan, X. Zeng, T. Li, Q. Chen, High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa, *Int. J. Oral Sci.* 12 (2020) 8.
- [12] G. Schett, B. Manger, D. Simon, R. Caporali, COVID-19 revisiting inflammatory pathways of arthritis, *Nat. Rev. Rheumatol.* 16 (2020) 465–470.
- [13] M.A. Tortorici, A.C. Walls, Y. Lang, C. Wang, Z. Li, D. Koerhuis, G.J. Boons, B. J. Bosch, F.A. Rey, R.J. de Groot, D. Velesler, Structural basis for human coronavirus attachment to sialic acid receptors, *Nat. Struct. Mol. Biol.* 26 (2019) 481–489.
- [14] Y. Watanabe, J.D. Allen, D. Wrapp, J.S. McLellan, M. Crispin, Site-specific glycan analysis of the SARS-CoV-2 spike, *Science* 369 (6501) (2020 Jul 17) 330–333, <https://doi.org/10.1126/science.abb9983>.
- [15] A. Shajahan, S. Archer-Hartmann, N.T. Supekar, A.S. Gleinich, C. Heiss, P. Azadi, Comprehensive characterization of N- and O- glycosylation of SARS-CoV-2 human receptor angiotensin converting enzyme 2, *bioRxiv* (2020). <https://doi.org/10.1101/2020.05.01.071688>.
- [16] C.A. Mitchell, K. Ramessar, B.R. O’Keefe, Antiviral lectins: selective inhibitors of viral entry, *Antivir. Res.* 142 (2017) 37–54.
- [17] D.S. Kim, M. Hosmillo, M.M. Alfajaro, J.Y. Kim, J.G. Park, K.Y. Son, E.H. Ryu, F. Sorgeolos, H.J. Kwon, S.J. Park, W.S. Lee, D. Cho, J. Kwon, J.S. Choi, M.I. Kang, I. Goodfellow, K.O. Cho, Both alpha2,3- and alpha2,6-linked sialic acids on o-linked glycoproteins act as functional receptors for porcine sapovirus, *PLoS Pathog.* 10 (2014), e1004172.
- [18] J.A. Ochoa-Alvarez, H. Krishnan, J.G. Pastorino, E. Nevel, D. Kephart, J.J. Lee, E. P. Retzbach, Y. Shen, M. Fatahzadeh, S. Baredes, E. Kalyoussef, M. Honma, M.

- E. Adelson, M.K. Kaneko, Y. Kato, M.A. Young, L. Deluca-Rapone, A.J. Shienbaum, K. Yin, L.D. Jensen, G.S. Goldberg, Antibody and lectin target podoplanin to inhibit oral squamous carcinoma cell migration and viability by distinct mechanisms, *Oncotarget* 6 (2015) 9045–9060.
- [19] J.A. Ochoa-Alvarez, H. Krishnan, Y. Shen, N.K. Acharya, M. Han, D.E. McNulty, H. Hasegawa, T. Hyodo, T. Senga, J.G. Geng, M. Kosciuk, S.S. Shin, J.S. Goydos, D. Temiakov, R.G. Nagele, G.S. Goldberg, Plant lectin can target receptors containing sialic Acid, exemplified by podoplanin, to inhibit transformed cell growth and migration, *PLoS One* 7 (2012), e41845.
- [20] C. Geisler, D.L. Jarvis, Effective glycoanalysis with Maackia amurensis lectins requires a clear understanding of their binding specificities, *Glycobiology* 21 (2011) 988–993.
- [21] P. Carpintero-Fernandez, M. Varela-Eirin, A. Lacetera, R. Gago-Fuentes, E. Fonseca, S. Martin-Santamaria, M.D. Mayan, New therapeutic strategies for osteoarthritis by targeting sialic acid receptors, *Biomolecules* 10 (2020) 21.
- [22] NCT04188665, Using MASL to Combat Oral Cancer, [Clinicaltrials.gov](https://clinicaltrials.gov), 2020.
- [23] Y. Shen, P.R. Khushf, X. Li, H. Ichikawa, A.P. Moreno, G.S. Goldberg, Src utilizes Cas to block gap junctional communication mediated by connexin43, *J. Biol. Chem.* 282 (2007) 18914–18921.
- [24] A. Mischler, V. Karakis, J. Mahinthakumar, C. Carberry, A. San Mi-guel, J. Rager, R. Fry, B.M. Rao, Two distinct trophectoderm lineage stem cells from human pluripotent stem cells, *bioRxiv* (2019), <https://doi.org/10.1101/762542>.
- [25] D.B. Alexander, H. Ichikawa, J.F. Bechberger, V. Valiunas, M. Ohki, C.C. Naus, T. Kunimoto, H. Tsuda, W.T. Miller, G.S. Goldberg, Normal cells control the growth of neighboring transformed cells independent of gap junctional communication and SRC activity, *Canc. Res.* 64 (2004) 1347–1358.
- [26] M.A. Zaki, P. Balachandran, S. Khan, M. Wang, R. Mohammed, M.H. Hetta, D. S. Pasco, I. Muhammad, Cytotoxicity and modulation of cancer-related signaling by (Z)- and (E)-3,4,3',5'-tetramethoxystilbene isolated from *Eugenia rigida*, *J. Nat. Prod.* 76 (2013) 679–684.
- [27] C.C. Chang, J. Zhang, L. Lombardi, A. Neri, R. Dalla-Favera, Mechanism of expression and role in transcriptional control of the proto-oncogene NFKB2/LYT-10, *Oncogene* 9 (1994) 923–933.
- [28] S. Jeon, M. Ko, J. Lee, I. Choi, S.Y. Byun, S. Park, D. Shum, S. Kim, Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs, *Antimicrobial Agents and Chemotherapy*, vol. 64, 2020.
- [29] M. Hoffmann, H. Kleine-Weber, S. Schroeder, N. Kruger, T. Herrler, S. Erichsen, T. S. Schiergens, G. Herrler, N.H. Wu, A. Nitsche, M.A. Muller, C. Drosten, S. Pohlmann, SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor, *Cell* 181 (2020) 271–280, e278.
- [30] R. Yamanouchi, K. Harada, T. Ferdous, Y. Ueyama, Low carbonyl reductase 1 expression is associated with poor prognosis in patients with oral squamous cell carcinoma, *Mol Clin Oncol* 8 (2018) 400–406.
- [31] K. Harada, T. Ferdous, Y. Ueyama, Establishment of 5-fluorouracil-resistant oral squamous cell carcinoma cell lines with epithelial to mesenchymal transition changes, *Int. J. Oncol.* 44 (2014) 1302–1308.
- [32] H. Krishnan, W.T. Miller, F.J. Blanco, G.S. Goldberg, Src and podoplanin forge a path to destruction, *Drug Discov. Today* 24 (2019) 241–249.
- [33] L.R. Loureiro, M.A. Carrascal, A. Barbas, J.S. Ramalho, C. Novo, P. Delannoy, P. A. Videira, Challenges in antibody development against tn and sialyl-tn antigens, *Biomolecules* 5 (2015) 1783–1809.
- [34] L.R. Loureiro, D.P. Sousa, D. Ferreira, W. Chai, L. Lima, C. Pereira, C.B. Lopes, V. G. Correia, L.M. Silva, C. Li, L.L. Santos, J.A. Ferreira, A. Barbas, A.S. Palma, C. Novo, P.A. Videira, Novel monoclonal antibody L2A5 specifically targeting sialyl-Tn and short glycans terminated by alpha-2-6 sialic acids, *Sci. Rep.* 8 (2018) 12196.
- [35] T. Hirano, M. Murakami, COVID-19: a new virus, but a familiar receptor and cytokine release syndrome, *Immunity* 52 (2020) 731–733.
- [36] S. Eguchi, T. Kawai, R. Scalia, V. Rizzo, Understanding angiotensin II type 1 receptor signaling in vascular pathophysiology, *Hypertension* 71 (2018) 804–810.
- [37] M. Murakami, D. Kamimura, T. Hirano, Pleiotropy and specificity: insights from the interleukin 6 family of cytokines, *Immunity* 50 (2019) 812–831.
- [38] E. de Wit, N. van Doremalen, D. Falzarano, V.J. Munster, SARS and MERS: recent insights into emerging coronaviruses, *Nat. Rev. Microbiol.* 14 (2016) 523–534.
- [39] L. Ding, X. Wang, X. Hong, L. Lu, D. Liu, IL-36 cytokines in autoimmunity and inflammatory disease, *Oncotarget* 9 (2018) 2895–2901.
- [40] L. Wang, B. Walia, J. Evans, A.T. Gewirtz, D. Merlin, S.V. Sitaraman, IL-6 induces NF-kappa B activation in the intestinal epithelia, *J. Immunol.* 171 (2003) 3194–3201.
- [41] A. Gopalakrishnan, P. Salgame, Toll-like receptor 2 in host defense against *Mycobacterium tuberculosis*: to be or not to be—that is the question, *Curr. Opin. Immunol.* 42 (2016) 76–82.
- [42] F. Ahsan, P. Moura-Alves, U. Guehlich-Bornhof, M. Klemm, S.H. Kaufmann, J. Maertzdorf, Role of interleukin 36gamma in host defense against *tuberculosis*, *J. Infect. Dis.* 214 (2016) 464–474.
- [43] A. Balato, M. Mattii, G. Caiazzo, A. Raimondo, C. Patruno, N. Balato, F. Ayala, S. Lembo, IL-36gamma is involved in psoriasis and allergic contact dermatitis, *J. Invest. Dermatol.* 136 (2016) 1520–1523.
- [44] A.R. Brasier, The nuclear factor-kappaB-interleukin-6 signalling pathway mediating vascular inflammation, *Cardiovasc. Res.* 86 (2010) 211–218.
- [45] T. Liu, L. Zhang, D. Joo, S.C. Sun, NF-kappaB signaling in inflammation, *Signal Transduct Target Ther* 2 (2017).
- [46] Y. Fang, F. Gao, Z. Liu, Angiotensin-converting enzyme 2 attenuates inflammatory response and oxidative stress in hyperoxic lung injury by regulating NF-kappaB and Nrf2 pathways, *QJM* 112 (2019) 914–924.
- [47] O. Takase, T. Marumo, N. Imai, J. Hirahashi, A. Takayanagi, K. Hishikawa, M. Hayashi, N. Shimizu, T. Fujita, T. Saruta, NF-kappaB-dependent increase in intrarenal angiotensin II induced by proteinuria, *Kidney Int.* 68 (2005) 464–473.
- [48] D.T. Graves, T.N. Milovanova, Mucosal immunity and the FOXO1 transcription factors, *Front. Immunol.* 10 (2019) 2530.
- [49] J. Zhang, Y. Yin, X. Lin, X. Yan, Y. Xia, L. Zhang, J. Cao, IL-36 induces cytokine IL-6 and chemokine CXCL8 expression in human lung tissue cells: implications for pulmonary inflammatory responses, *Cytokine* 99 (2017) 114–123.
- [50] C.A. Piantadosi, C.M. Withers, R.R. Bartz, N.C. MacGarvey, P. Fu, T.E. Sweeney, K. E. Welty-Wolf, H.B. Suliman, Heme oxygenase-1 couples activation of mitochondrial biogenesis to anti-inflammatory cytokine expression, *J. Biol. Chem.* 286 (2011) 16374–16385.
- [51] Z.C. Yuan, W.D. Xu, X.Y. Liu, X.Y. Liu, A.F. Huang, L.C. Su, Biology of IL-36 signaling and its role in systemic inflammatory diseases, *Front. Immunol.* 10 (2019) 2532.
- [52] X. Tang, R.H. Du, R. Wang, T.Z. Cao, L.L. Guan, C.Q. Yang, Q. Zhu, M. Hu, X.Y. Li, Y. Li, L.R. Liang, Z.H. Tong, B. Sun, P. Peng, H.Z. Shi, Comparison of hospitalized patients with ARDS caused by COVID-19 and H1N1, *Chest* 158 (2020) 195–205.
- [53] National Institutes of Health, Therapeutic management of adults with COVID-19. <https://www.covid19treatmentguidelines.nih.gov/therapeutic-management/>. (Accessed 26 March 2021).
- [54] U.S.F.a.D. Administration, Emergency use authorization. <https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization#%20covid19euas>. (Accessed 26 March 2021).
- [55] Centers for Disease Control. Prevention, Provisional death counts for coronavirus disease 2019 (COVID-19). <https://www.cdc.gov/nchs/nvss/vsrr/covid19/index.htm>. (Accessed 26 March 2021).
- [56] C. Huang, Y. Wang, X. Li, L. Ren, J. Zhao, Y. Hu, L. Zhang, G. Fan, J. Xu, X. Gu, Z. Cheng, T. Yu, J. Xia, Y. Wei, W. Wu, X. Xie, W. Yin, H. Li, M. Liu, Y. Xiao, H. Guo, L. Guo, J. Xie, G. Wang, R. Jiang, Z. Gao, Q. Jin, J. Wang, B. Cao, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, *Lancet* 395 (2020) 497–506.
- [57] G. Schett, M. Sticherling, M.F. Neurath, COVID-19: risk for cytokine targeting in chronic inflammatory diseases? *Nat. Rev. Immunol.* 20 (2020) 271–272.
- [58] P. Sarzi-Puttini, V. Giorgi, S. Sirotti, D. Marotto, S. Ardiccione, G. Rizzardini, S. Antinori, M. Galli, COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome? *Clin. Exp. Rheumatol.* 38 (2020) 337–342.
- [59] L.A. Henderson, S.W. Canna, G.S. Schuler, S. Volpi, P.Y. Lee, K.F. Kernan, R. Caricchio, S. Mahmud, M.M. Hazen, O. Halyabar, K.J. Hoyt, J. Han, A.A. Grom, M. Gattorno, A. Ravelli, F. De Benedetti, E.M. Behrens, R.Q. Cron, P.A. Nigrovic, On the alert for cytokine storm: immunopathology in COVID-19, *Arthritis Rheum.* 72 (2020) 1059–1063.
- [60] R.M. Viner, E. Whittaker, Kawasaki-like disease: emerging complication during the COVID-19 pandemic, *Lancet* 395 (2020) 1741–1743.
- [61] S. Riphagen, X. Gomez, C. Gonzalez-Martinez, N. Wilkinson, P. Theocharis, Hyperinflammatory shock in children during COVID-19 pandemic, *Lancet* 395 (2020) 1607–1608.
- [62] T. Kewan, F. Covut, M.J. Al-Jaghbeer, L. Rose, K.V. Gopalakrishna, B. Akbik, Tocilizumab for treatment of patients with severe COVID-19: a retrospective cohort study, *EclinicalMedicine* 24 (2020) 100418.
- [63] F. Gotzinger, B. Santiago-Garcia, A. Noguera-Julian, M. Lanasa, L. Lancelli, F. I. Calo Carducci, N. Gabrovská, S. Velizarova, P. Prunk, V. Osterman, U. Krivec, A. Lo Vecchio, D. Shingadia, A. Soriano-Arandes, S. Melendo, M. Lanari, L. Pierantonio, N. Wagner, A.G. L'Huillier, U. Heineinger, N. Ritz, S. Bandi, N. Krajcar, S. Roglic, M. Santos, C. Christiaens, M. Creuven, D. Buonsenso, S. B. Welch, M. Bogyi, F. Brinkmann, M. Tebruegge, C.-S.G. ptbnet, COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study, *Lancet Child Adolesc Health* 4 (9) (2020 Sep) 653–661, [https://doi.org/10.1016/S2352-4642\(20\)30177-2](https://doi.org/10.1016/S2352-4642(20)30177-2). Epub 2020 Jun 25.
- [64] R. Wu, L. Wang, H.D. Kuo, A. Shannar, R. Peter, P.J. Chou, S. Li, R. Hudlikar, X. Liu, Z. Liu, G.J. Poiani, L. Amorosa, L. Brunetti, A.N. Kong, An update on current therapeutic drugs treating COVID-19, *Curr Pharmacol Rep* (2020) 1–15.
- [65] A. Puszta, S. Bardocz, S.W. Ewen, Uses of plant lectins in bioscience and biomedicine, *Front. Biosci.* 13 (2008) 1130–1140.
- [66] I.F. Pryme, S. Bardocz, A. Puszta, S.W. Ewen, Suppression of growth of tumour cell lines in vitro and tumours in vivo by mistletoe lectins, *Histol. Histopathol.* 21 (2006) 285–299.
- [67] S.S. Hasan, G.M. Ashraf, N. Banu, Galectins - potential targets for cancer therapy, *Canc. Lett.* 253 (2007) 25–33.
- [68] N. Friedman, H. Alter, M. Hindiyyeh, E. Mendelson, Y. Shemer Avni, M. Mandelboim, Human coronavirus infections in Israel: epidemiology, clinical symptoms and summer seasonality of HCoV-HKU1, *Viruses* 10 (2018).
- [69] W.J. Guan, Z.Y. Ni, Y. Hu, W.H. Liang, C.Q. Ou, J.X. He, L. Liu, H. Shan, C.L. Lei, D. S.C. Hui, B. Du, L.J. Li, G. Zeng, K.Y. Yuen, R.C. Chen, C.L. Tang, T. Wang, P. Y. Chen, J. Xiang, S.Y. Li, J.L. Wang, Z.J. Liang, Y.X. Peng, L. Wei, Y. Liu, Y.H. Hu, P. Peng, J.M. Wang, J.Y. Liu, Z. Chen, G. Li, Z.J. Zheng, S.Q. Qiu, J. Luo, C.J. Ye, S. Y. Zhu, N.S. Zhong, C. China Medical Treatment, Expert group for, clinical characteristics of coronavirus disease 2019 in China, *N. Engl. J. Med.* 382 (2020) 1708–1720.
- [70] M. Honma, T. Shibuya, M. Fujii, S. Iinuma, N. Saito, M. Kishibe, A. Ishida-Yamamoto, Maackia amurensis seed lectin can suppress IL-22induced hyperproliferative reconstituted epidermis, *Journal of Dermatological Science* 86 (2017) E46.